Want to join the conversation?
Boehringer Ingelheim and $LLY announced plans to conduct two outcome trials investigating diabetes medicine Jardiance (empagliflozin) for the treatment of people with chronic heart failure. The trials are targeted to begin within next 12 months and are planned to enroll people with chronic heart failure both with and without type 2 diabetes.
People seem to be cold about the $HAL earnings! Honestly, I expected more stock action by now.
$TSLA's Musk says Neuralink will take on AI prominence. Apparently, he wants to avoid a "Terminator" kind situation.
$JCP shares rebounded and now in green territory after saying it will hire 800 consultants as part of a beauty expansion that will include 70 new Sephora store-in-store locations.
The latest earnings report by $VZ shows how it is losing customers despite offering the unlimited data plans, a record for the company.